Galera Therapeutics, Reducing Toxicity & Increasing Anti-Cancer Efficacy for Patients

Innovation That Matters

Dr. Robert Beardsley, Founder and Chief Operating Officer at Galera Therapeutics, shares his company’s R&D vision and pipeline, aimed at improving treatments and outcomes for cancer patients.

Recently, Galera’s lead product candidate, avasopasem manganese (GC4419) received Fast Track and Breakthrough Therapy Designations for the reduced incidence and severity of severe oral mucositis (SOM) – a common painful side effect experienced by 70% of head and neck cancer patients undergoing radiotherapy.

Tune in to hear more on Galera’s pipeline, the science behind small molecule dismutase mimetics, Robert’s insights for the future, and the partnerships enhancing Galera’s success. Watch now.

Subscribe to WXPress

Receive our newsletter and information on upcoming events.